NASDAQ:ATRC - AtriCure Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $90.50
  • Forecasted Upside: 27.45 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$71.01
▼ -5.71 (-7.44%)

This chart shows the closing price for ATRC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AtriCure Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATRC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATRC

Analyst Price Target is $90.50
▲ +27.45% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for AtriCure in the last 3 months. The average price target is $90.50, with a high forecast of $120.00 and a low forecast of $75.00. The average price target represents a 27.45% upside from the last price of $71.01.

This chart shows the closing price for ATRC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 contributing investment analysts is to buy stock in AtriCure. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/4/2021SVB LeerinkBoost Price TargetOutperform$100.00 ➝ $110.00High
11/4/2021Needham & Company LLCBoost Price TargetBuy$90.00 ➝ $92.00High
8/5/2021Canaccord GenuityBoost Price TargetBuy$102.00 ➝ $120.00High
8/5/2021Needham & Company LLCLower Price TargetBuy$91.00 ➝ $90.00High
8/5/2021SVB LeerinkBoost Price TargetOutperform$95.00 ➝ $100.00High
8/5/2021OppenheimerDowngradeOutperform ➝ Market PerformHigh
6/15/2021Stifel NicolausBoost Price TargetPositive ➝ Buy$72.00 ➝ $85.00High
5/26/2021SVB LeerinkBoost Price TargetOutperform$78.00 ➝ $95.00High
5/17/2021Needham & Company LLCReiterated RatingBuy$91.00High
5/14/2021JPMorgan Chase & Co.Boost Price TargetOverweight$70.00 ➝ $81.00Low
4/29/2021Piper SandlerBoost Price Target$70.00 ➝ $85.00Medium
4/29/2021SVB LeerinkReiterated RatingBuyHigh
4/28/2021Needham & Company LLCBoost Price TargetBuy$74.00 ➝ $81.00High
4/28/2021OppenheimerBoost Price TargetOutperform$65.00 ➝ $75.00High
4/28/2021BTIG ResearchBoost Price TargetBuy$69.00 ➝ $76.00High
4/28/2021Canaccord GenuityBoost Price TargetBuy$77.00 ➝ $102.00High
4/12/2021Canaccord GenuityBoost Price TargetBuy$69.00 ➝ $77.00Low
2/24/2021SVB LeerinkBoost Price TargetOutperform$65.00 ➝ $78.00Low
2/24/2021Needham & Company LLCBoost Price TargetBuy$63.00 ➝ $74.00High
2/24/2021Canaccord GenuityBoost Price TargetBuy$53.00 ➝ $69.00Low
1/29/2021Piper SandlerBoost Price TargetOverweight$50.00 ➝ $66.00Medium
1/21/2021BTIG ResearchBoost Price TargetIn-Line ➝ Buy$56.00 ➝ $66.00Low
12/18/2020Needham & Company LLCBoost Price TargetBuy$53.00 ➝ $63.00High
12/14/2020SVB LeerinkBoost Price TargetOutperform$60.00 ➝ $65.00High
11/6/2020Needham & Company LLCLower Price TargetBuy$63.00 ➝ $53.00Medium
7/29/2020JPMorgan Chase & Co.Boost Price TargetOverweight$48.00 ➝ $57.00High
7/29/2020SVB LeerinkBoost Price TargetOutperform$55.00 ➝ $60.00High
7/29/2020Piper SandlerBoost Price TargetPositive ➝ Overweight$47.00 ➝ $50.00High
7/28/2020BTIG ResearchReiterated RatingBuy$56.00High
5/11/2020BTIG ResearchBoost Price TargetBuy$45.00 ➝ $56.00High
5/11/2020SVB LeerinkBoost Price TargetOutperform$50.00 ➝ $55.00High
5/11/2020OppenheimerBoost Price TargetOutperform$45.00 ➝ $52.00High
5/8/2020Needham & Company LLCReiterated RatingBuy$49.00Medium
4/30/2020Canaccord GenuityBoost Price TargetBuy$41.00 ➝ $45.00High
4/29/2020BTIG ResearchReiterated RatingBuy$45.00High
4/28/2020JPMorgan Chase & Co.Lower Price TargetOverweight$47.00 ➝ $39.00Medium
4/19/2020OppenheimerInitiated CoverageOutperform$45.00Low
4/13/2020Canaccord GenuityLower Price TargetBuy$51.00 ➝ $41.00Medium
4/6/2020OppenheimerInitiated CoverageOutperform$45.00High
2/19/2020Piper SandlerBoost Price Target$40.00 ➝ $50.00Medium
2/19/2020Needham & Company LLCBoost Price TargetBuy$48.00 ➝ $52.00High
2/19/2020BTIG ResearchBoost Price TargetBuy$42.00 ➝ $48.00High
2/19/2020Canaccord GenuityReiterated RatingBuy ➝ Buy$43.00 ➝ $51.00High
2/6/2020BTIG ResearchInitiated CoverageBuy$42.00Medium
1/27/2020Piper SandlerReiterated RatingBuy$40.00High
1/24/2020Needham & Company LLCReiterated RatingBuy$39.00 ➝ $48.00Low
1/21/2020BTIG ResearchReiterated RatingBuy ➝ Outperform$42.00Low
9/6/2019JPMorgan Chase & Co.Reiterated RatingBuyMedium
8/13/2019BTIG ResearchReiterated RatingBuy$35.00High
8/13/2019Northland SecuritiesDowngradeOutperform ➝ Market Perform$30.00High
8/12/2019Piper Jaffray CompaniesSet Price TargetBuy$40.00Medium
8/12/2019Needham & Company LLCSet Price TargetBuy$39.00Medium
4/26/2019Northland SecuritiesReiterated RatingBuyHigh
4/12/2019JPMorgan Chase & Co.Initiated CoverageOverweight$37.00Medium
4/2/2019BTIG ResearchUpgradeNeutral ➝ Buy$35.00High
3/28/2019Needham & Company LLCReiterated RatingBuy$39.00High
3/5/2019BTIG ResearchReiterated RatingHoldLow
11/2/2018Needham & Company LLCReiterated RatingBuy$39.00High
10/12/2018Needham & Company LLCReiterated RatingBuy$39.00Medium
10/9/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$37.00 ➝ $40.00Low
10/4/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$36.00 ➝ $39.00High
8/2/2018Stifel NicolausBoost Price TargetBuy$32.00 ➝ $34.00High
8/2/2018BTIG ResearchReiterated RatingHoldHigh
8/2/2018Canaccord GenuityReiterated RatingBuy$37.00High
8/2/2018Needham & Company LLCReiterated RatingBuy$32.00 ➝ $36.00High
6/27/2018BTIG ResearchReiterated RatingHoldMedium
6/27/2018Canaccord GenuityBoost Price TargetBuy$27.00 ➝ $35.00Medium
6/27/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$23.00 ➝ $32.00Medium
6/26/2018Piper Jaffray CompaniesBoost Price TargetOverweight$30.00Medium
6/18/2018Needham & Company LLCBoost Price TargetBuy$26.00 ➝ $32.00High
4/27/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$22.00 ➝ $23.00High
4/27/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$23.00 ➝ $26.00High
2/27/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$24.00 ➝ $26.00High
2/27/2018Needham & Company LLCReiterated RatingBuy$23.00High
1/16/2018Needham & Company LLCReiterated RatingBuy$25.00 ➝ $23.00Low
12/10/2017Piper Jaffray CompaniesReiterated RatingBuy$24.00Low
11/2/2017Canaccord GenuityLower Price TargetBuy$28.00 ➝ $24.00N/A
11/2/2017Needham & Company LLCLower Price TargetBuy ➝ Buy$26.00 ➝ $25.00N/A
10/9/2017Canaccord GenuityReiterated RatingBuy$28.00N/A
7/30/2017Stifel NicolausReiterated RatingBuy$25.00Medium
7/28/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$25.00 ➝ $26.00High
6/16/2017SVB LeerinkReiterated RatingOutperform$26.00Low
5/30/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$26.00Low
5/5/2017Needham & Company LLCReiterated RatingBuy$23.00 ➝ $25.00High
4/17/2017Canaccord GenuityReiterated RatingBuy$22.00Low
3/20/2017Northland SecuritiesReiterated RatingBuy$24.00Low
3/6/2017BTIG ResearchDowngradeBuy ➝ NeutralN/A
3/1/2017Needham & Company LLCReiterated RatingBuy$23.00N/A
2/6/2017Canaccord GenuityReiterated RatingBuy$20.00N/A
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
7/30/2021
  • 1 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/29/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/28/2021
  • 10 very positive mentions
  • 24 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 10 very positive mentions
  • 24 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
AtriCure logo
AtriCure, Inc. engages in the development, manufacture, and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in Mason, OH.
Read More

Today's Range

Now: $71.01
Low: $70.49
High: $77.00

50 Day Range

MA: $74.51
Low: $67.21
High: $87.14

52 Week Range

Now: $71.01
Low: $42.50
High: $89.18

Volume

179,001 shs

Average Volume

302,330 shs

Market Capitalization

$3.26 billion

P/E Ratio

74.75

Dividend Yield

N/A

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of AtriCure?

The following Wall Street research analysts have issued reports on AtriCure in the last year: BTIG Research, Canaccord Genuity, JPMorgan Chase & Co., Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Stifel Nicolaus, SVB Leerink LLC, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for ATRC.

What is the current price target for AtriCure?

8 Wall Street analysts have set twelve-month price targets for AtriCure in the last year. Their average twelve-month price target is $90.50, suggesting a possible upside of 27.4%. Canaccord Genuity has the highest price target set, predicting ATRC will reach $120.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $75.00 for AtriCure in the next year.
View the latest price targets for ATRC.

What is the current consensus analyst rating for AtriCure?

AtriCure currently has 1 hold rating and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATRC will outperform the market and that investors should add to their positions of AtriCure.
View the latest ratings for ATRC.

What other companies compete with AtriCure?

How do I contact AtriCure's investor relations team?

AtriCure's physical mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company's listed phone number is (513) 755-4100. The official website for AtriCure is www.atricure.com.